Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Radiotherapy management of brain metastases using conventional linear accelerator

M. Matzenauer, D. Vrana, Z. Vlachova, K. Cwiertka, O. Kalita, B. Melichar,

. 2016 ; 160 (3) : 412-416. [pub] 20160913

Language English Country Czech Republic

Document type Evaluation Study, Journal Article

Persistent link   https://www.medvik.cz/link/bmc17016661

BACKGROUND AND AIMS: As treatments for primary cancers continue to improve life expectancy, unfortunately, brain metastases also appear to be constantly increasing and life expectancy for patients with brain metastases is low. Longer survival and improved quality of life may be achieved using localised radiological and surgical approaches in addition to low dose corticosteroids. Stereotactic brain radiotherapy is one rapidly evolving localized radiation treatment. This article describes our experience with stereotactic radiotherapy using a linear accelerator. METHODS: We reviewed patients treated with stereotactic radiotherapy, from the time of its introduction into daily practice in our Department of Oncology in 2014. We collected the data on patient treatment and predicted survival based on prognostic indices and actual patient outcome. RESULTS: A total of 10 patients were treated by stereotactic radiotherapy, in one case in combination with whole brain radiotherapy and hippocampal sparing. There was no significant treatment related toxicity during the treatment or follow-up and due to the small number of fractions, the overall tolerance of the treatment was excellent. The patient intrafractional movement in all cases was under 1 mm suggesting that 1 mm margin around the CTV to create the PTV is sufficient and also that patient immobilization using the thermoplastic mask compared with invasive techniques, is feasible. We also found that prognostic indices such as the Graded Prognostic Assessment provide accurate predictions of patient survival. CONCLUSIONS: Based on our current evidence, patients with brain metastases fit enough, should be considered for stereotactic radiotherapy treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17016661
003      
CZ-PrNML
005      
20170519133136.0
007      
ta
008      
170516s2016 xr f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2016.043 $2 doi
035    __
$a (PubMed)27641139
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Matzenauer, Marcel $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
245    10
$a Radiotherapy management of brain metastases using conventional linear accelerator / $c M. Matzenauer, D. Vrana, Z. Vlachova, K. Cwiertka, O. Kalita, B. Melichar,
520    9_
$a BACKGROUND AND AIMS: As treatments for primary cancers continue to improve life expectancy, unfortunately, brain metastases also appear to be constantly increasing and life expectancy for patients with brain metastases is low. Longer survival and improved quality of life may be achieved using localised radiological and surgical approaches in addition to low dose corticosteroids. Stereotactic brain radiotherapy is one rapidly evolving localized radiation treatment. This article describes our experience with stereotactic radiotherapy using a linear accelerator. METHODS: We reviewed patients treated with stereotactic radiotherapy, from the time of its introduction into daily practice in our Department of Oncology in 2014. We collected the data on patient treatment and predicted survival based on prognostic indices and actual patient outcome. RESULTS: A total of 10 patients were treated by stereotactic radiotherapy, in one case in combination with whole brain radiotherapy and hippocampal sparing. There was no significant treatment related toxicity during the treatment or follow-up and due to the small number of fractions, the overall tolerance of the treatment was excellent. The patient intrafractional movement in all cases was under 1 mm suggesting that 1 mm margin around the CTV to create the PTV is sufficient and also that patient immobilization using the thermoplastic mask compared with invasive techniques, is feasible. We also found that prognostic indices such as the Graded Prognostic Assessment provide accurate predictions of patient survival. CONCLUSIONS: Based on our current evidence, patients with brain metastases fit enough, should be considered for stereotactic radiotherapy treatment.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádory mozku $x mortalita $x radioterapie $x sekundární $7 D001932
650    _2
$a studie proveditelnosti $7 D005240
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a částice - urychlovače $7 D010315
650    _2
$a radiochirurgie $x přístrojové vybavení $x mortalita $7 D016634
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
655    _2
$a hodnotící studie $7 D023362
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vrána, David $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic; Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic $7 xx0103187
700    1_
$a Vlachová, Zuzana $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $7 xx0231645
700    1_
$a Ćwiertka, Karel, $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $d 1961- $7 xx0018322
700    1_
$a Kalita, Ondřej, $u Department of Neurosurgery, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $d 1972- $7 xx0046875
700    1_
$a Melichar, Bohuslav, $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic $d 1965- $7 skuk0000853
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 160, č. 3 (2016), s. 412-416
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20170516 $b ABA008
991    __
$a 20170518091907 $b ABA008
999    __
$a ok $b bmc $g 1205807 $s 977470
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 160 $c 3 $d 412-416 $e 20160913 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20170516

Find record

Citation metrics

Logged in users only

Archiving options